Immunopharmacological studies of qingkaining, a Chinese blended medicine: effects on experimental autoimmune uveoretinitis in the rat.
Qingkaining, a blended Chinese medicine, is reported to be effective in treating patients with uveitis in China. In this study, the immunomodulatory effectiveness of this drug was evaluated on experimental autoimmune uveoretinitis (EAU) induced by S-antigen (S-Ag). Rats treated with high (2.5 cc/kg/day) and low (1 cc/kg/day) doses of Qingkaining, high (10 mg/kg/day) and low (3 mg/kg/day) doses of Cyclosporine A (CsA) and a combination of high or low dose of Qingkaining and low dose CsA were compared by the following parameters: clinical manifestations, histopathology, skin delayed-type hypersensitivity (DTH) reactions, lymphocyte proliferative responses and serum anti-S-antigen antibody production. The incidences of clinically and histopathologically determined EAU were 14.29% and 28.57% respectively in the rats treated with high and low doses of Qingkaining in comparison to 57.14% and none in the rats treated with low and high doses of CsA. EAU did not develop in the rats treated with the combination of low dose CsA and low or high doses of Qingkaining. The skin DTH reaction showed a diminished response in the rats treated with either Qingkaining or CsA. However, the lymphocyte proliferative responses and anti-S-Ag antibody were not effected in the rats treated with Qingkaining alone. This study demonstrates that Qingkaining is a potent immunosuppressive agent in this model for human disease. The experimental data support the clinical effectiveness of Qingkaining in the treatment of patients with uveitis.